Published in BMJ on November 24, 2011
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet (2013) 2.66
The treatment of type 2 diabetes. Dtsch Arztebl Int (2014) 2.66
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med (2014) 2.17
Long-term effects of goshajinkigan in prevention of diabetic complications: a randomized open-labeled clinical trial. Evid Based Complement Alternat Med (2014) 1.42
Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Front Endocrinol (Lausanne) (2013) 1.34
The thrifty phenotype hypothesis revisited. Diabetologia (2012) 1.28
Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol (2012) 1.26
Cardiovascular effects of gliptins. Nat Rev Cardiol (2013) 1.23
Angiogenic Factors and Cytokines in Diabetic Retinopathy. J Clin Cell Immunol (2013) 1.15
Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care (2012) 1.12
Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia (2014) 1.06
Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence. Circ Cardiovasc Qual Outcomes (2016) 1.02
Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci (2013) 0.99
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther (2013) 0.98
Hypoglycemia in type 2 diabetes: current controversies and changing practices. Front Endocrinol (Lausanne) (2012) 0.95
Influencing factors on cardiac structure and function beyond glycemic control in patients with type 2 diabetes mellitus. Cardiovasc Diabetol (2013) 0.88
Recent HbA1c values and mortality risk in type 2 diabetes. population-based case-control study. PLoS One (2013) 0.86
Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes? PLoS One (2013) 0.85
Management of hyperglycemia in type 2 diabetes: evidence and uncertainty. Cardiovasc Diabetol (2013) 0.85
Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open (2016) 0.84
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies. Diabetes Metab J (2015) 0.83
Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes. Patient Prefer Adherence (2014) 0.83
Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy by Aspelund et al. (2011) Diabetologia 54:2525-2532. Graefes Arch Clin Exp Ophthalmol (2012) 0.83
Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis (2013) 0.83
The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud (2014) 0.82
Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol (2012) 0.82
Evidence that multiple defects in lipid regulation occur before hyperglycemia during the prodrome of type-2 diabetes. PLoS One (2014) 0.80
Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Am Heart Assoc (2015) 0.80
Direct effects of PPARα agonists on retinal inflammation and angiogenesis may explain how fenofibrate lowers risk of severe proliferative diabetic retinopathy. Diabetes (2013) 0.79
Mendelian Randomization and Type 2 Diabetes. Cardiovasc Drugs Ther (2016) 0.79
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovasc Diabetol (2016) 0.79
Glucose control and cardiovascular outcomes: reorienting approach. Front Endocrinol (Lausanne) (2012) 0.79
Trends in adherence to dietary recommendations among Korean type 2 diabetes mellitus patients. Nutr Res Pract (2015) 0.78
Intradermal insulin delivery: a promising future for diabetes management. J Diabetes Sci Technol (2014) 0.78
Optimal treatment of diabetic retinopathy. Ther Adv Endocrinol Metab (2013) 0.78
Pharmacological primary and secondary cardiovascular prevention among diabetic patients in a multiethnic general practice population: still room for improvements. BMC Health Serv Res (2013) 0.78
Role of genetic mutations in folate-related enzyme genes on Male Infertility. Sci Rep (2015) 0.78
Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality. Cardiovasc Diabetol (2012) 0.77
Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? Open Cardiovasc Med J (2012) 0.77
Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrol (2016) 0.76
Treated glycosylated hemoglobin levels in individuals with diabetes mellitus vary little by health status: A retrospective cohort study. Medicine (Baltimore) (2016) 0.76
A review of cardiovascular outcomes in the treatment of people with type 2 diabetes. Diabetes Ther (2014) 0.76
Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Diabetes Res (2016) 0.76
Target values of cardiovascular risk factors are not associated with all-cause mortality in patients with type 2 diabetes mellitus. PLoS One (2015) 0.75
Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013. J Clin Med Res (2016) 0.75
Hard end points are needed for intensive glycaemic control in patients with type 2 diabetes. BMJ (2012) 0.75
Time to be cautious about prescribing sulfonylureas? Br J Gen Pract (2015) 0.75
Prevention of complications in type 2 diabetes: is drug glucose control evidence based? Br J Gen Pract (2017) 0.75
Identified single-nucleotide polymorphisms and haplotypes at 16q22.1 increase diabetic nephropathy risk in Han Chinese population. BMC Genet (2014) 0.75
Stabilization of high-risk plaques. Cardiovasc Diagn Ther (2016) 0.75
Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes-Associated Retinopathy. Clin Transl Sci (2016) 0.75
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. Curr Geriatr Rep (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06
Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract (1995) 12.51
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet (2009) 10.55
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia (2009) 6.55
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J (2005) 5.40
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet (1999) 4.81
A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes (1970) 4.57
UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia (1991) 4.50
Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation (2004) 4.34
Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med (2009) 4.19
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol (2007) 4.06
Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg (1999) 3.81
Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med (2006) 3.60
Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.49
Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care (1999) 3.36
Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care (2000) 3.35
Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med (1997) 3.35
Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications (2003) 3.33
Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ (2001) 3.12
Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia (2010) 2.71
Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol (2008) 2.61
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care (2009) 2.50
Methods for combining randomized clinical trials: strengths and limitations. Stat Med (1987) 2.49
Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care (2004) 2.46
Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol (2009) 2.39
Sequential methods for random-effects meta-analysis. Stat Med (2010) 2.33
The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J (2007) 2.17
Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother (1996) 2.14
Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol (2004) 2.14
The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One (2011) 2.02
Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care (1995) 1.99
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care (2009) 1.89
Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J (1996) 1.83
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia (2009) 1.59
Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes (2010) 1.53
Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM) Diabetes Care (1992) 1.42
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev (2011) 1.42
Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care (1996) 1.39
Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis (2009) 1.35
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) Diabetes Care (1999) 1.32
Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care (2000) 1.28
Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care (2008) 1.27
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia (2005) 1.26
Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab (2008) 1.26
Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia (2001) 1.25
Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care (2009) 1.20
Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. CMAJ (2005) 1.20
3-year follow-up of clinical and behavioral improvements following a multifaceted diabetes care intervention: results of a randomized controlled trial. Diabetes Educ (2010) 1.19
Comparison of three protocols for tight glycemic control in cardiac surgery patients. Diabetes Care (2009) 1.16
Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. Br Med J (Clin Res Ed) (1985) 1.15
Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes (1982) 1.08
Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract (2000) 1.05
Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol (2006) 1.05
Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Fam Pract (2009) 1.01
Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes. Effects on well-being at 1 year. Diabetes Care (1998) 1.01
Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med (2010) 0.96
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2009) 0.94
Effect of blood glucose control on peripheral nerve function in diabetic patients. Mayo Clin Proc (1983) 0.93
Improving glycaemic control self-efficacy and glycaemic control behaviour in Chinese patients with type 2 diabetes mellitus: randomised controlled trial. J Clin Nurs (2010) 0.93
The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab (2009) 0.90
Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res (2006) 0.90
Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J (2001) 0.87
Effects of five-year intensive multifactorial intervention on the serum amyloid A and macroangiopathy in patients with short-duration type 2 diabetes mellitus. Chin Med J (Engl) (2009) 0.87
Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest (2004) 0.87
Effects of structured hospital-based care compared with standard care for Type 2 diabetes-The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial. Diabet Med (2007) 0.85
Diabetes Care Protocol: effects on patient-important outcomes. A cluster randomized, non-inferiority trial in primary care. Diabet Med (2010) 0.85
Effects of moderate intensity glycemic control after cardiac surgery. Ann Thorac Surg (2010) 0.84
Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. J Nephrol (2002) 0.84
The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab (2001) 0.84
Health-related quality of life in the VA Feasibility Study on glycemic control and complications in type 2 diabetes mellitus. J Diabetes Complications (2005) 0.83
The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin Cardiol (2000) 0.83
The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res (2009) 0.82
WITHDRAWN: Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev (2015) 0.81
Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care (1998) 0.81
Intensive insulin treatment reduces transient ischaemic episodes during acute coronary events in diabetic patients. Acta Cardiol (2002) 0.81
Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med (2013) 20.70
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA (2007) 11.87
Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med (2007) 11.62
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med (2012) 10.34
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA (2003) 8.21
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev (2015) 7.31
Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med (2014) 6.93
Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet (2004) 6.35
Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet (2009) 5.43
Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet (2008) 5.05
Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med (2013) 5.02
Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology (2010) 4.19
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol (2007) 4.06
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev (2011) 3.73
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J (2011) 3.72
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
TXNIP regulates peripheral glucose metabolism in humans. PLoS Med (2007) 3.27
Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation (2008) 3.23
Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol (2010) 2.77
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev (2012) 2.74
Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev (2011) 2.72
Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol (2008) 2.66
Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med (2006) 2.65
Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol (2008) 2.61
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care (2009) 2.56
Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol (2009) 2.39
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol (2008) 2.31
Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med (2015) 2.25
Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest (2004) 2.24
Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry (2013) 2.22
No major differences in 30-day outcomes in high-risk patients randomized to off-pump versus on-pump coronary bypass surgery: the best bypass surgery trial. Circulation (2010) 2.21
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev (2013) 2.18
The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepatobiliary randomized clinical trials. Am J Gastroenterol (2005) 2.12
Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study. Diabetologia (2014) 2.08
Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res (2005) 2.06
High body mass index is a weak predictor for difficult and failed tracheal intubation: a cohort study of 91,332 consecutive patients scheduled for direct laryngoscopy registered in the Danish Anesthesia Database. Anesthesiology (2009) 2.06
The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One (2011) 2.02
Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev (2014) 2.01
New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. Nat Genet (2012) 1.90
Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ (2006) 1.88
Disclosure of investigators' recruitment performance in multicenter clinical trials: a further step for research transparency. PLoS Med (2011) 1.86
Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol (2007) 1.86
Randomised controlled trial of total compared with subtotal hysterectomy with one-year follow up results. BJOG (2003) 1.82
Decreased expression of heat shock protein 72 in skeletal muscle of patients with type 2 diabetes correlates with insulin resistance. Diabetes (2002) 1.78
Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials (2010) 1.77
Commentary: The evolution of methods to assess the effects of treatments, illustrated by the development of treatments for diphtheria, 1825-1918. Int J Epidemiol (2011) 1.76
Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med (2013) 1.75
Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes (2005) 1.73
Regulation and function of FTO mRNA expression in human skeletal muscle and subcutaneous adipose tissue. Diabetes (2009) 1.72
Genetic and epigenetic factors are associated with expression of respiratory chain component NDUFB6 in human skeletal muscle. J Clin Invest (2007) 1.65
Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ (2004) 1.64
Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev (2011) 1.63
Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA (2003) 1.62
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. Atherosclerosis (2010) 1.60
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol (2010) 1.57
Sexuality after total vs. subtotal hysterectomy. Acta Obstet Gynecol Scand (2004) 1.57
Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men. J Physiol (2009) 1.52
Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. Am J Gastroenterol (2006) 1.52
Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care (2008) 1.50
Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate. Intensive Care Med (2014) 1.49
Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol (2007) 1.48
Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med (2014) 1.48
Studies of variations of the cyclin-dependent kinase inhibitor 1C and the cyclin-dependent kinase 4 genes in relation to type 2 diabetes mellitus and related quantitative traits. J Mol Med (Berl) (2005) 1.45
Systematic Reviews of Anesthesiologic Interventions Reported as Statistically Significant: Problems with Power, Precision, and Type 1 Error Protection. Anesth Analg (2015) 1.45
Skin care education and individual counselling versus treatment as usual in healthcare workers with hand eczema: randomised clinical trial. BMJ (2012) 1.45
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev (2011) 1.42
Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study. Diabetologia (2014) 1.40
Early versus delayed laparoscopic cholecystectomy for people with acute cholecystitis. Cochrane Database Syst Rev (2013) 1.40
Catering in a large hospital--does serving from a buffet system meet the patients' needs? Clin Nutr (2008) 1.39